ICMJE DISCLOSURE FORM

Date:	12/9/2023	
Your Name:	Shuji Murakami	
Manuscript Title:	Will perioperative pembrolizumab treatment change perioperative treatment strategies for resectable NSCLC?	
Manuscript Number (if known):	TLCR-23-578	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
	Time frame: Since the initial planning of the work					
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	⊠ None	Click the tab key to add additional rows.			
Time frame: p		Time frame: past 36 month	S			
2	Grants or contracts from	D None				
	any entity (if not	AstraZeneca	Institution			
	indicated in item	Takeda	Institution			
	#1 above).	Chugai Pharma	Institution			
		Sanofi	Institution			
		MSD	Institution			
		Daiichi Sankyo	Institution			
		Ono Pharmaceutical	Institution			
		Janssen Pharma	Institution			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑ None □ □ □ □	
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for	□ None AstraZeneca Chugai Pharma Takeda Eli Lilly MSD Pfizer Novartis Taiho Pharmaceutical ⊠ None	MeMeMeMeMeMeMeMeMeMeMeMeMe
	expert testimony		
7	Support for attending meetings and/or travel	Image: None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board,	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid			
11	Stock or stock options	None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None 		
13	Other financial or non-financial interests	⊠ None		
Please place an "X" next to the following statement to indicate your agreement:				